CDK18 (PCTK3) as a Drug Target and Biomarker: A Promising Approach in Cancer Treatment

Target Name: CDK18

NCBI ID: G5129

CDK18

CDK18 (PCTK3) as a Drug Target and Biomarker: A Promising Approach in Cancer Treatment

CDK18 (PCTK3) is a protein that plays a critical role in cell proliferation and has been identified as a potential drug target and biomarker in cancer treatment. CDK18 is a key regulator of the G1/S transition, which is a critical step in the cell cycle that leads to the completion of DNA replication and the start of cell division. Discovered in 2008, CDK18 has been shown to promote the G1/S transition in various cell types, including human cancer cells. The potential implications of CDK18 as a drug target and biomarker make it an attractive target for cancer researchers and pharmaceutical companies.

CDK18 as a Drug Target

CDK18 has been shown to promote the G1/S transition, which is a critical step in the cell cycle that leads to the completion of DNA replication and the start of cell division. This process is crucial for the growth and development of cancer cells, and inhibiting CDK18 has been shown to be a promising approach in cancer treatment.

One of the main advantages of targeting CDK18 is its potential to inhibit cell proliferation and promote cell death. CDK18 is a key regulator of the G1/S transition, which is a critical step in the cell cycle that leads to the completion of DNA replication and the start of cell division. By inhibiting CDK18, researchers have found that they can disrupt the G1/S transition and prevent cancer cells from dividing and proliferating.

Another potential mechanism by which CDK18 may be targeted is its role in cell survival. CDK18 has been shown to promote the growth and survival of various cancer cell types, including human cancer cells. By inhibiting CDK18, researchers have found that they can reduce the growth and survival of cancer cells.

CDK18 as a Biomarker

CDK18 has also been identified as a potential biomarker for cancer diagnosis and treatment. By measuring the levels of CDK18 in cancer cells, researchers have found that higher levels of CDK18 are associated with a more aggressive and less responsive cancer cell. This suggests that CDK18 may be a useful biomarker for predicting the effectiveness of cancer treatments and identifying potential drug targets.

In addition to its potential as a biomarker, CDK18 has also been shown to be a potential drug target. By inhibiting CDK18, researchers have found that they can reduce the growth and survival of cancer cells, which suggests that CDK18 may be a useful target for cancer treatments.

Conclusion

In conclusion, CDK18 (PCTK3) is a protein that plays a critical role in cell proliferation and has been identified as a potential drug target and biomarker in cancer treatment. The potential implications of CDK18 as a drug target and biomarker make it an attractive target for cancer researchers and pharmaceutical companies. Further studies are needed to fully understand the role of CDK18 in cancer treatment and to develop effective strategies for targeting it.

Protein Name: Cyclin Dependent Kinase 18

Functions: May play a role in signal transduction cascades in terminally differentiated cells

The "CDK18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets